Teva Absorbs Ivax In $7.4-Billion Bid - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Teva Absorbs Ivax In $7.4-Billion Bid

ePT--the Electronic Newsletter of Pharmaceutical Technology

Teva Absorbs Ivax In $7.4-Billion Bid

TEVA Pharmaceutical Industries (Netanya, Israel) has signed an agreement to acquire IVAX Corporation (Miami, FL) for approximately $7.4 billion, further cementing Teva’s control of the generics industry.

In a prepared statement, TEVA’s President and CEO Israel Makov said, “The combination of our two complementary businesses will allow TEVA to expand and strengthen our global generic and branded businesses with additional products, a deeper pipeline, and a wider presence in new therapeutic areas and growth markets.”

With the IVAX purchase Teva, gains a strong presence in Latin America and in Central and Eastern Europe, and further expands its operations in North America and Europe. IVAX also brings complementary product lines in generics, a significant respiratory business, and a pipeline of generic and proprietary products in the areas of respiratory, CNS, and oncology. TEVA expects to generate sales of over $7 billion, and will operate in over 50 countries with an employee base of approximately 25,000 people.

–George Koroneos

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here